What Is FGF-21?
Fibroblast Growth Factor 21 (FGF-21) is an atypical member of the fibroblast growth factor superfamily that functions primarily as an endocrine hormone rather than a paracrine or autocrine signaling molecule. Originally characterized in 2000, FGF-21 is a 181-amino acid protein (~19.6 kDa) produced predominantly by the liver, but also expressed in adipose tissue, skeletal muscle, and the pancreas in response to specific metabolic cues.
Unlike most FGF family members that act locally, FGF-21 circulates in the bloodstream to coordinate systemic energy homeostasis. Its unique mechanism requires a co-receptor — β-Klotho (KLB) — to form a ternary signaling complex with fibroblast growth factor receptor 1c (FGFR1c), conferring tissue-specific activity primarily in adipose tissue, liver, and the central nervous system.
FGF-21 has become one of the most intensively studied metabolic hormones of the past decade, with preclinical and clinical research demonstrating roles in glucose homeostasis, lipid metabolism, fatty liver disease, longevity signaling, and neuroprotection. Multiple FGF-21 analogs are in clinical development, including the leading candidate efruxifermin (AKF-176), which has reached Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH).
> Research Use Only. FGF-21 is a research compound not approved for human use. All information on this page is for scientific education purposes only and does not constitute medical advice.
---
Molecular Structure and Receptor Biology
Primary Structure
FGF-21 is encoded by the FGF21 gene on chromosome 19q13.33 in humans. The mature secreted form is 181 amino acids with a classical signal peptide directing it into the secretory pathway. As an "endocrine FGF," FGF-21 lacks the heparan sulfate-binding domain present in most FGF family members — an absence that enables long-range systemic endocrine signaling rather than local tissue action.
Key structural features include:
- •A conserved β-trefoil fold core common to the FGF family
- •An N-terminal domain responsible for FGFR1c engagement
- •A C-terminal tail critical for high-affinity β-Klotho binding
- •Multiple proteolytic cleavage sites that limit native half-life to approximately 2 hours
The FGFR1c / β-Klotho Ternary Complex
FGF-21 requires two membrane-bound proteins to signal efficiently:
1. FGFR1c — the primary tyrosine kinase receptor that transduces the signal
2. β-Klotho (KLB) — the obligate co-receptor that provides high-affinity FGF-21 binding
β-Klotho expression is tissue-restricted (primarily liver, adipose, hypothalamus), explaining why circulating FGF-21 acts on a limited set of target organs despite widespread distribution. Research has shown FGF-21 can also signal through FGFR2 and FGFR3 in β-Klotho-expressing tissues, though FGFR1c remains dominant in adipose tissue and liver (PMID: 27125737; PMID: 22248288).
Upon ternary complex formation and FGFR1c transphosphorylation, FGF-21 activates downstream cascades including:
- •MAPK/ERK pathway — transcriptional regulation of metabolic genes
- •PI3K/AKT pathway — insulin sensitization and GLUT4 trafficking
- •AMPK activation — energy sensing and mitochondrial biogenesis
- •PGC-1α induction — thermogenesis and fatty acid oxidation
- •KLF15 and FGF response elements — lipid and glucose metabolic gene programs
---
Physiological Regulation and Tissue Sources
FGF-21 is dynamically regulated across tissues in response to nutritional state and metabolic stress:
| Tissue | Role | Primary Stimulus |
|---|---|---|
| Liver (hepatocytes) | Dominant circulating source | Fasting, PPARα activation, high-fat diet, alcohol |
| White adipose tissue | Autocrine/paracrine | PPARγ agonists, cold exposure |
| Brown adipose tissue | Local and circulating | β3-adrenergic stimulation |
| Skeletal muscle | Stress myokine | Mitochondrial dysfunction, prolonged exercise |
| Pancreas | Minor contributor | Nutrient stimulation |
Key Regulatory Stimuli
- •Fasting drives hepatic PPARα-dependent FGF-21 production, promoting ketogenesis and fatty acid mobilization
- •High-carbohydrate diets elevate FGF-21 via ChREBP activation — a paradoxical nutrient-sensing response
- •Acute alcohol ingestion rapidly induces hepatic FGF-21 as part of the fasting-mimicry response to ethanol metabolism
- •Mitochondrial dysfunction triggers muscle-derived FGF-21 as a stress myokine signaling systemic metabolic remodeling
- •Exercise induces muscle FGF-21 during prolonged aerobic work, contributing to adipose lipolysis
---
Metabolic Research: Insulin Sensitivity and Glucose Homeostasis
FGF-21 was identified early in its research history as a potent insulin sensitizer. In obese rodent models, pharmacological FGF-21 administration consistently:
- •Reduced fasting glucose and insulin concentrations
- •Suppressed hepatic gluconeogenesis
- •Enhanced adipose tissue glucose uptake (adipose, not muscle — an important mechanistic distinction)
- •Lowered circulating triglycerides and LDL cholesterol
- •Increased energy expenditure without suppressing food intake at physiological doses
Mechanistically, FGF-21's insulin-sensitizing effects are partially mediated through adiponectin induction. FGF-21 is one of the most potent known inducers of adiponectin secretion from white adipose tissue, and adiponectin-null mice show blunted metabolic responses to FGF-21 treatment, establishing a critical mediator pathway.
A comprehensive 2018 review catalogued FGF-21 as a "versatile regulator of metabolic homeostasis" — acting on liver, adipose, and brain to coordinate the fasting-to-fed transition and protect against diet-induced metabolic dysfunction (PMID: 29727594).
---
Lipid Metabolism and Adipose Tissue Research
White Adipose Tissue
In white adipose tissue (WAT), FGF-21 drives:
- •Lipolysis — activation of hormone-sensitive lipase and ATGL, releasing free fatty acids for oxidation
- •Adiponectin secretion — systemic insulin sensitization
- •Thermogenic gene expression — browning via UCP1, Cidea, and PRDM16 upregulation
- •Lipid uptake inhibition — reduced lipid storage in already-metabolically stressed adipocytes
Brown Adipose Tissue
FGF-21 has a potent thermogenic action in brown adipose tissue (BAT):
- •Activates UCP1-mediated uncoupled respiration (heat generation)
- •Enhances PGC-1α and PRDM16 expression
- •Increases sympathetic nervous system-independent thermogenesis
- •Research suggests brain-mediated FGF-21 → sympathetic → BAT axis as a key energy expenditure pathway distinct from direct adipose receptor activation
Liver Lipid Metabolism
In the liver, FGF-21 suppresses de novo lipogenesis by downregulating SREBP-1c, while simultaneously inducing fatty acid oxidation genes via PPARα-dependent and independent mechanisms — creating a coordinated anti-steatotic program.
---
MASH / NASH and Liver Fibrosis Research
Why FGF-21 Is Relevant to MASH
FGF-21 has emerged as a central research target for metabolic dysfunction-associated steatohepatitis (MASH), for several mechanistic reasons:
1. Direct anti-fibrotic signaling — FGF-21 suppresses hepatic stellate cell (HSC) activation, attenuating collagen deposition and fibrosis progression
2. Steatosis reduction — Reduced hepatic lipid accumulation through VLDL suppression and enhanced β-oxidation
3. Anti-inflammatory effects — Attenuation of hepatic NF-κB and TNF-α-mediated inflammatory signaling
4. Insulin sensitization — Reversal of the systemic insulin resistance driving MASH pathogenesis
5. Adipose-liver crosstalk — Reducing excess adipose-derived free fatty acid flux to the liver
Clinical Development of FGF-21 Analogs for MASH
Native FGF-21 has a short plasma half-life (~2 hours) requiring engineering for therapeutic use. Two analogs have progressed to clinical trials:
Efruxifermin (Akero Therapeutics):
A bivalent Fc-fusion protein with ~7-day half-life, optimized for resistance to FAP protease cleavage. Phase 2 results in patients with fibrosis stage 2-3 MASH demonstrated:
- •39.7% vs. 17.1% fibrosis improvement (≥1 stage without MASH worsening) in the efruxifermin vs. placebo groups
- •Significant reductions in hepatic fat fraction (MRI-PDFF) and ALT
- •Improvements in insulin resistance, lipid profiles, and adiponectin
Phase IIa results in compensated NASH cirrhosis showed hepatic steatosis improvement but did not meet the primary fibrosis endpoint at 36 weeks (PMC9832280). A 2025 NEJM study further evaluated efruxifermin in cirrhosis, and Phase 3 trials (SYNCHRONY-CIRRHOSIS) are ongoing.
A 2025 meta-analysis of efruxifermin across randomized controlled trials confirmed significant improvement in fibrosis without MASH worsening (RR 1.83, 95% CI 1.17–2.84) compared to placebo (PMC12163238).
Pegbelfermin (Bristol-Myers Squibb):
A PEGylated FGF-21 analog with demonstrated Phase 2 efficacy in reducing hepatic fat, but development was discontinued in 2024 after Phase 2b data failed to meet pre-specified efficacy thresholds.
The divergence in clinical outcomes between efruxifermin and pegbelfermin has informed understanding of the importance of analog engineering, receptor occupancy, and FAP resistance in FGF-21 therapeutic development.
---
Longevity and Anti-Aging Research
FGF-21 as a Lifespan Regulator
Preclinical evidence positions FGF-21 among a small group of hormones that can measurably extend lifespan in mammalian models:
Systemic FGF-21 overexpression in transgenic mice extends median lifespan by 30-40%, accompanied by reduced cancer incidence, improved metabolic health, and maintained cognitive function — at the cost of reduced bone density and suppressed IGF-1.
Adipocyte-specific FGF-21 overexpression in diet-induced obese mice produced lifespans up to 3.3 years (vs. ~2.5 years controls), with protection against obesity, insulin resistance, and hepatic steatosis — importantly, this tissue-targeted approach avoided systemic IGF-1 suppression and bone loss, suggesting organ-specific FGF-21 strategies may capture longevity benefits with reduced side effects (PMID: 40527315).
AAV Gene Therapy (2023): Intramuscular delivery of AAV1-FGF21 in aged mice produced sustained circulating FGF-21 elevation, extended healthspan and lifespan, and reversed age-related insulin resistance, body weight gain, neuromuscular decline, and cognitive impairment — establishing gene therapy-mediated FGF-21 elevation as a longevity research platform (PMID: 37699965).
The FGF-21 / IGF-1 Axis
FGF-21 and IGF-1 form a counter-regulatory hormonal pair central to longevity research:
- •Elevated FGF-21 suppresses hepatic IGF-1 production via GH resistance induction
- •The FGF-21↑ / IGF-1↓ hormonal state closely mirrors the longevity-associated endocrine profile observed in caloric restriction
- •FGF-21 mediates a portion of the metabolic and longevity benefits seen with dietary restriction, as FGF-21 knockout mice show blunted CR responses
- •Sustained IGF-1 suppression from excess FGF-21 carries trade-offs (bone loss, reduced muscle anabolism) — an important consideration for long-duration FGF-21 research protocols
FGF-21 knockout mice studied in 2024 showed progressive metabolic and inflammatory dysfunction consistent with premature metabolic aging, reinforcing FGF-21's role as an endogenous regulator of aging trajectories (PMID: 38653921).
---
Neuroprotection and Neuroscience Research
Blood-Brain Barrier Penetration
FGF-21 crosses the blood-brain barrier, acting on hypothalamic neurons expressing FGFR1c and β-Klotho to regulate energy balance, circadian activity, and neurological function independently of peripheral metabolic effects.
Cerebrovascular Aging
FGF-21 has been shown to suppress cerebrovascular aging via AMPK-dependent mitochondrial biogenesis enhancement and inhibition of p53-mediated cellular senescence in vascular cells — positioning it as a potential research compound in cerebrovascular aging and vascular dementia models (PMID: 27364911).
Alzheimer's Research
A 2019 review in Current Neuropharmacology examined FGF-21-mediated neuroprotection in Alzheimer's-type dementia, identifying:
- •AMPK/mTOR suppression of tau hyperphosphorylation
- •Attenuation of amyloid-β-induced neurotoxicity
- •Reduction of neuroinflammatory microglial activation
- •Enhancement of synaptic plasticity via BDNF-related pathways
ALS and Motor Neuron Disease Research
A study published in Aging found markedly elevated FGF-21 in ALS patient muscle biopsies, localized to atrophic myofibers, with concomitant elevation in spinal cord tissue. Elevated circulating FGF-21 correlated with enhanced survival in ALS patients, and FGF-21 supplementation mitigated stress-induced motor neuron cytotoxicity in vitro — identifying FGF-21 as an endogenous neuroprotective myokine in motor neuron disease research.
---
Skeletal Muscle Research
Skeletal muscle produces FGF-21 as a myokine during:
- •Prolonged aerobic exercise
- •Mitochondrial stress (mitophagy induction, electron transport chain dysfunction)
- •Caloric restriction and fasting
- •Glucocorticoid exposure
Muscle-derived FGF-21 contributes to adipose lipolysis and energy substrate mobilization during exercise. In mitochondrial myopathy research, FGF-21 serves as a sensitive biomarker — plasma FGF-21 is significantly elevated in patients with mitochondrial disease and correlates with disease severity, outperforming traditional biomarkers in some diagnostic applications.
FGF-21 deficiency in skeletal muscle-specific knockout models accelerates mitochondrial dysfunction, reduced exercise capacity, and impaired metabolic flexibility, demonstrating the importance of local FGF-21 signaling for muscle mitochondrial health.
---
FGF-21 vs. Other Metabolic Research Compounds
| Parameter | FGF-21 | GLP-1 Agonists | Adiponectin |
|---|---|---|---|
| Primary origin | Liver / adipose | Gut L-cells | Adipose tissue |
| Key mechanism | Energy expenditure ↑, liver fat ↓ | Appetite ↓, insulin secretion ↑ | Insulin sensitization |
| MASH fibrosis | Direct anti-fibrotic | Indirect via steatosis | Limited data |
| Appetite suppression | Modest | Potent | Minimal |
| Bone effects | Reduction at high doses | Neutral/positive | Positive |
| Lifespan extension | Strong preclinical data | Emerging | Moderate |
| Clinical stage | Phase 3 (MASH) | Approved for T2D/obesity | Preclinical only |
The complementary mechanisms of GLP-1 agonists (caloric intake reduction) and FGF-21 (energy expenditure increase + direct liver effects) have driven research interest in combination approaches. A April 2026 study from the University of Oklahoma highlighted FGF-21's mechanism as fundamentally distinct from GLP-1 — increasing metabolic energy burning rather than appetite suppression — reinforcing the rationale for combination research strategies.
---
Pharmacokinetics and Research Analog Development
Native FGF-21 is challenging for research use due to:
- •Short half-life (~2 hours): N-terminal cleavage by FAP; C-terminal cleavage by DPP-4-like enzymes
- •Low molecular weight (~19.6 kDa): Rapid renal clearance
- •Aggregation tendency: Limits formulation stability
Research and therapeutic analogs address these limitations through:
| Strategy | Example | Outcome |
|---|---|---|
| PEGylation | Pegbelfermin | Extended t½, reduced immunogenicity |
| Fc-fusion (bivalent) | Efruxifermin | ~7-day t½, FAP-resistant |
| Point mutations | Multiple candidates | Increased stability, potency |
| Anti-FGFR1/KLB bispecific antibodies | BFKB8488A (Roche) | Receptor activation without FGF-21 scaffold |
---
Research Caveats and Study Design Considerations
Researchers working with FGF-21 should account for:
Species Translation Challenges:
Rodent studies have consistently shown robust FGF-21 effects, but translation to humans has proven partial. Differences in β-Klotho tissue distribution, receptor expression levels, and endogenous FGF-21 activity between species require careful consideration.
FGF-21 Resistance:
Chronic FGF-21 elevation (obesity, sustained pharmacological dosing) induces downregulation of FGFR1c and β-Klotho in target tissues — a desensitization mechanism analogous to leptin resistance. Research protocols must account for this when designing chronic exposure studies.
Bone Effects:
Supraphysiological or chronic FGF-21 in rodent models suppresses osteoblast differentiation via Wnt pathway inhibition, producing bone loss. This appears dose- and duration-dependent, and human trial data from efruxifermin suggest bone density monitoring is warranted in long-duration studies.
Sex Differences:
Preclinical and clinical data suggest sex-specific differences in FGF-21 signaling magnitude and tissue targets. Female rodents often show more pronounced FGF-21 longevity phenotypes; careful sex-stratified analysis is essential in metabolic FGF-21 research.
---
Current Research Landscape (2025-2026)
The FGF-21 field is advancing on multiple simultaneous fronts:
1. Phase 3 MASH trials: Efruxifermin SYNCHRONY-NASH and SYNCHRONY-CIRRHOSIS programs are the most advanced clinical FGF-21 applications
2. GLP-1 + FGF-21 combinations: Multiple research groups are exploring additive or synergistic metabolic and hepatic effects
3. Gene therapy: AAV-FGF21 platforms have moved from mouse longevity models toward primate safety studies
4. Endogenous FGF-21 inducers: Small molecules that upregulate hepatic FGF-21 transcription (e.g., PPARα agonists in combination, fasting mimetics) represent an alternative research strategy
5. FGF-21 as biomarker: Serum FGF-21 is being validated as a diagnostic marker in MASH staging, metabolic syndrome severity scoring, and mitochondrial myopathy diagnosis
---
Key Research References
- •Fisher FM, Maratos-Flier E. Understanding the Physiology of FGF21. Annu Rev Physiol. 2016;78:223-241. PMID: 26654352
- •Kliewer SA, Mangelsdorf DJ. A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21. Cell Metab. 2019;29(2):246-253. PMID: 28559437
- •Markan KR, et al. FGF21: A Versatile Regulator of Metabolic Homeostasis. Endocrinology. 2020;161(1). PMID: 29727594
- •Fang M, et al. FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression. Cell Metab. 2025. PMID: 40527315
- •Mou Z, et al. Long-term effects of fat-directed FGF21 gene therapy in aged female mice. Aging Cell. 2023. PMID: 37699965
- •Chen X, et al. FGF21 represses cerebrovascular aging via AMPK. PMID: 27364911
- •Investigation of Metabolic and Inflammatory Disorder in Aging FGF21 Knockout Mouse. 2024. PMID: 38653921
- •Harrison SA, et al. Phase IIa trial of efruxifermin for compensated NASH cirrhosis. JHEP Reports. 2023. PMC9832280
- •Systematic review and meta-analysis of efruxifermin for NASH/MASH fibrosis. PMC12163238
---
Summary
FGF-21 is among the most scientifically compelling metabolic research peptides currently under investigation. Acting as a liver-derived endocrine hormone via the FGFR1c/β-Klotho receptor complex, it coordinates energy homeostasis across adipose tissue, liver, and the brain — simultaneously addressing insulin resistance, hepatic steatosis and fibrosis, adipose thermogenesis, and neurological aging. Its emerging role as a longevity signal in preclinical models, combined with Phase 3 clinical data in MASH, establishes FGF-21 as a uniquely multi-dimensional research compound at the intersection of metabolic disease, aging biology, and liver research.
All compounds described are for Research Use Only (RUO). This article is educational and does not constitute clinical or medical advice of any kind.